Medication info
Abicl Tablets (Acyclovir)

Abicl Tablets (Acyclovir)

Prescription medicationTabletIntravenous injection
Ingredient · strength
Acyclovir›200mg / 1 tablet
Manufacturer / importer
Eden Pharma Co., Ltd.
Appearance
Light blue round tablet
Packaging
30 tablets/bottle, 200 tablets/bottle
Approval status
Active

MFDS item code 202001041 · Approved 2020.02.17 · Insurance code 628901610

Summary

Main use
Treatment of herpes zoster; treatment and prevention of herpes simplex; treatment of chickenpox in children 2 years of age and older
Who receives it
Adults · Children
Adult administration
○ Adults 1. Treatment of herpes simplex virus infections 1) Administer acyclovir 200 mg per dose 5 times daily at 4-hour intervals for 5 days. Treatment may be extended in cases of severe initial infection. 2) In patients with severe immunodeficiency (e.g., after bone marrow transplantation) or impaired gastrointestinal absorption, the dose may be increased to 400 mg per dose or the route of administration may be changed to intravenous injection. 3) It is preferable to begin treatment as soon as possible after infection; in recurrent cases, treatment should preferably begin at the first sign of prodromal symptoms or lesions. 2. Prevention of herpes simplex infections in patients with normal immune function 1) Administer 200 mg of this drug per dose 4 times daily at approximately 6-hour intervals. Alternatively, 400 mg per dose may be administered twice daily at 12-hour intervals. 2) Thereafter, the dose may be reduced to 200 mg per dose 2 ~ 3 times daily after confirming its efficacy. 3) To assess the natural course of the disease, treatment should be discontinued periodically every 6 ~ 12 months in patients receiving long-term treatment. 3. Prevention of herpes simplex infections in patients with impaired immune function 1) Administer 200 mg of this drug per dose 4 times daily at approximately 6-hour intervals. 2) In patients with severe immunodeficiency (e.g., after bone marrow transplantation) or impaired gastrointestinal absorption, the dose may be increased to 400 mg per dose or the route of administration may be changed to intravenous injection. 3) Administer during the period of risk of infection. 4. Treatment of herpes zoster infections 1) Administer 800 mg of this drug per dose 5 times daily at approximately 4-hour intervals, except during sleep, for a total of 7 days. 2) Intravenous administration should be considered in patients with severe immunodeficiency or impaired gastrointestinal absorption. 3) It is preferable to begin treatment as soon as possible after infection; the earlier treatment is started, the better the effect. ○ Patients with renal impairment As patients with renal impairment are more susceptible to neuropsychiatric adverse reactions, caution should be exercised, such as by extending the dosing interval or reducing the dose. 1. Treatment of herpes simplex infections The oral dose is generally not higher than the amount that would accumulate with intravenous administration. However, in patients with severe renal impairment (creatinine clearance less than 10 mL per minute), it is preferable to administer 200 mg of this drug every 12 hours. 2. Treatment of varicella-zoster virus infections 1) In patients with creatinine clearance less than 10 mL per minute, it is preferable to reduce the dose to 800 mg of this drug per dose twice daily at approximately 12-hour intervals. 2) In patients with creatinine clearance of 10 ~ 25 mL per minute, it is preferable to reduce the dose to 800 mg of this drug per dose 3 times daily at approximately 8-hour intervals.
Child administration
○ Children 1. Treatment of herpes simplex infections and prevention of herpes simplex infections in patients with impaired immune function 1) Age 2 years and older: Same as the adult dosage. 2) Under 2 years: Administer 1/2 of the adult dose. 3) Reliable data are not yet available on the prevention of herpes simplex virus infections in patients with normal immune function. 2. Treatment of chickenpox in children 2 years and older: Administer 20 mg per kg of body weight of this drug per dose (maximum 800 mg per dose) 4 times daily for 5 days. Treatment should be started as soon as possible after the chickenpox rash appears, preferably within 24 hours after the rash appears.

Ingredients

Manufacturer
Eden Pharma Co., Ltd.

Efficacy & effects

Treatment of herpes zoster; treatment and prevention of herpes simplex; treatment of chickenpox in children 2 years of age and older

  • Primary genital herpes
  • recurrent genital herpes
  • herpes simplex virus infection
  • varicella-zoster virus infection
  • acute pain
  • chickenpox
View approved original text

This medication is used to treat and prevent herpes simplex virus infections including primary and recurrent genital herpes. It is also effective in the treatment of varicella-zoster virus infections and particularly helps relieve acute pain. However, it should be noted that its efficacy for postherpetic neuralgia has not yet been established. It is also used to treat chickenpox in children over 2 years old, improving symptoms. Overall, this drug is effective in treating various viral infections of the skin and mucous membranes.

How it is given

Adult administration

○ Adults 1. Treatment of herpes simplex virus infections 1) Administer acyclovir 200 mg per dose 5 times daily at 4-hour intervals for 5 days. Treatment may be extended in cases of severe initial infection. 2) In patients with severe immunodeficiency (e.g., after bone marrow transplantation) or impaired gastrointestinal absorption, the dose may be increased to 400 mg per dose or the route of administration may be changed to intravenous injection. 3) It is preferable to begin treatment as soon as possible after infection; in recurrent cases, treatment should preferably begin at the first sign of prodromal symptoms or lesions. 2. Prevention of herpes simplex infections in patients with normal immune function 1) Administer 200 mg of this drug per dose 4 times daily at approximately 6-hour intervals. Alternatively, 400 mg per dose may be administered twice daily at 12-hour intervals. 2) Thereafter, the dose may be reduced to 200 mg per dose 2 ~ 3 times daily after confirming its efficacy. 3) To assess the natural course of the disease, treatment should be discontinued periodically every 6 ~ 12 months in patients receiving long-term treatment. 3. Prevention of herpes simplex infections in patients with impaired immune function 1) Administer 200 mg of this drug per dose 4 times daily at approximately 6-hour intervals. 2) In patients with severe immunodeficiency (e.g., after bone marrow transplantation) or impaired gastrointestinal absorption, the dose may be increased to 400 mg per dose or the route of administration may be changed to intravenous injection. 3) Administer during the period of risk of infection. 4. Treatment of herpes zoster infections 1) Administer 800 mg of this drug per dose 5 times daily at approximately 4-hour intervals, except during sleep, for a total of 7 days. 2) Intravenous administration should be considered in patients with severe immunodeficiency or impaired gastrointestinal absorption. 3) It is preferable to begin treatment as soon as possible after infection; the earlier treatment is started, the better the effect. ○ Patients with renal impairment As patients with renal impairment are more susceptible to neuropsychiatric adverse reactions, caution should be exercised, such as by extending the dosing interval or reducing the dose. 1. Treatment of herpes simplex infections The oral dose is generally not higher than the amount that would accumulate with intravenous administration. However, in patients with severe renal impairment (creatinine clearance less than 10 mL per minute), it is preferable to administer 200 mg of this drug every 12 hours. 2. Treatment of varicella-zoster virus infections 1) In patients with creatinine clearance less than 10 mL per minute, it is preferable to reduce the dose to 800 mg of this drug per dose twice daily at approximately 12-hour intervals. 2) In patients with creatinine clearance of 10 ~ 25 mL per minute, it is preferable to reduce the dose to 800 mg of this drug per dose 3 times daily at approximately 8-hour intervals.

Child administration

○ Children 1. Treatment of herpes simplex infections and prevention of herpes simplex infections in patients with impaired immune function 1) Age 2 years and older: Same as the adult dosage. 2) Under 2 years: Administer 1/2 of the adult dose. 3) Reliable data are not yet available on the prevention of herpes simplex virus infections in patients with normal immune function. 2. Treatment of chickenpox in children 2 years and older: Administer 20 mg per kg of body weight of this drug per dose (maximum 800 mg per dose) 4 times daily for 5 days. Treatment should be started as soon as possible after the chickenpox rash appears, preferably within 24 hours after the rash appears.

Precautions

This medication should not be used in patients who are allergic to this drug or any of its components or have previously shown hypersensitivity to valacyclovir. Caution should be taken when administering this medication to patients with poor kidney function, as it may cause adverse reactions in the central nervous system. Patients with impaired liver function should be administered the drug carefully due to the risk of further deterioration of liver function. Caution should be exercised when using this medication in infants and children, especially in neonates or low-birth-weight infants, as safety has not been established and it should only be administered when necessary. Elderly patients may be more likely to have reduced kidney function, which can lead to increased blood concentration of this medication and a higher susceptibility to adverse reactions; therefore, dosage and administration intervals should be adjusted and used cautiously. While using this medication, serious allergic reactions such as anaphylactic shock may rarely occur. If symptoms such as low blood pressure, difficulty breathing, or chest tightness occur, administration should be discontinued immediately and appropriate treatment should be sought. Skin rashes, fever, blisters, urticaria, etc. may occur, and in severe cases, serious skin reactions such as Stevens-Johnson syndrome or Lyell's syndrome may occur, so administration should be stopped if symptoms appear. CNS symptoms may include altered consciousness, disorientation, decreased concentration, aggressive behavior, hallucinations, confusion, seizures, drowsiness, and anxiety, particularly in elderly patients and those with impaired kidney function. Renal-related abnormal symptoms such as reduced kidney function, hematuria, and proteinuria may appear, so caution is advised. Hematological and lymphatic system abnormalities may lead to leukopenia, anemia, bleeding, and purpura; any unusual symptoms should be discussed with a doctor. Liver function abnormalities, hepatitis, and jaundice may occur, so it is important to periodically monitor liver function test results. Gastrointestinal symptoms such as gastritis, constipation, nausea, vomiting, and abdominal pain may occur, and if severe, treatment should be discontinued and care sought. Adequate hydration is necessary while using this medication, particularly in high doses, to prevent dehydration and reduce the risk of nephrotoxicity. If symptoms do not improve or worsen during the course of treatment, alternative treatment methods should be contemplated. Patients with weakened immunity may be more suitable for intravenous administration. During administration of this drug, caution should be exercised when engaging in activities that require alertness, such as driving or operating machinery, as altered consciousness may occur. This drug may interact with other medications, particularly those affecting kidney function or those such as probenecid, cimetidine, theophylline, and mycophenolate mofetil, so consultation with a doctor or pharmacist is advised. Women who are pregnant or may become pregnant should carefully consider the implications of taking this drug on the fetus, and breastfeeding should be ceased during treatment. In the event of overdose, serious symptoms such as coma, seizures, and renal failure may occur, necessitating immediate medical attention for appropriate treatment. Prolonged high-dose use of this medication may impact genetic abnormalities or reproductive function, so it is essential to adhere to the recommended dosage.

Side effects

  • anaphylactic shock
  • anaphylactoid reaction
  • hypotension
  • dyspnea
  • chest tightness
  • photosensitivity reaction
  • fixed drug eruption
  • rash
  • fever
  • vesicles
Show 117 more
  • urticarial erythema
  • urticaria
  • alopecia
  • erythema multiforme
  • Stevens-Johnson syndrome
  • toxic epidermal necrolysis
  • altered consciousness
  • disorientation
  • impaired concentration
  • aggressive behavior
  • depersonalization
  • anxiety
  • ataxia
  • coma
  • confusion
  • delirium
  • stuttering
  • encephalopathy
  • hallucination
  • psychosis
  • convulsions
  • drowsiness
  • tremors
  • agitation
  • forgetfulness
  • insomnia
  • anxiety
  • soliloquy
  • paresthesia
  • ataxia
  • gait disturbance
  • involuntary movements
  • nystagmus
  • dizziness
  • renal failure
  • crystalluria
  • elevated BUN
  • elevated serum creatinine
  • hematuria
  • proteinuria
  • urinary red blood cell casts
  • pyuria
  • leucocytoclastic vasculitis
  • lymphadenopathy
  • hemorrhage
  • purpura
  • anemia
  • leukopenia
  • leukocytosis
  • eosinophilia
  • lymphocytosis
  • thrombocytosis
  • granulocytopenia
  • thrombocytopenia
  • basophilia
  • hepatitis
  • liver dysfunction
  • jaundice
  • abnormal liver function tests
  • hepatomegaly
  • gastritis
  • thirst
  • constipation
  • acute pancreatitis
  • diarrhea
  • soft stools
  • abdominal pain
  • epigastric pain
  • colicky pain
  • nausea
  • vomiting
  • dyspepsia
  • loss of appetite
  • glossitis
  • fever
  • peripheral edema
  • syncope
  • pallor
  • muscle weakness
  • fatigue
  • generalized malaise
  • headache
  • arthralgia
  • myalgia
  • arrhythmia
  • chest pain
  • hypertension
  • hypotension
  • tachycardia
  • palpitations
  • urinary obstruction
  • dysuria
  • glycosuria
  • pneumonia
  • pharyngitis
  • pleural effusion
  • pain
  • hearing loss
  • conjunctivitis
  • visual disturbances
  • taste disorders
  • sweating
  • hyponatremia
  • decreased serum protein
  • elevated total cholesterol
  • elevated triglycerides
  • elevated serum potassium
  • decreased serum albumin
  • anxiety
  • coma
  • convulsions
  • somnolence
  • confusion
  • hallucination
  • agitation
  • epileptic seizure
  • comatose state

Not everyone experiences these, and they can vary from person to person.

Storage

This medication must be stored in a tightly sealed container to prevent exposure to air and moisture. It is preferable to maintain a storage temperature between 1 to 30 degrees Celsius at room temperature.

Appearance and packaging

Appearance

Light blue round tablet

Package unit

30 tablets/bottle, 200 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.